PAREXEL Ranked a Top CRO in CenterWatch Global Investigative Site Relationship Survey
April 03 2017 - 9:00AM
Business Wire
Company recognized for sponsor/site
relationship quality
PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services organization, today announced
that it was named a top contract research organization (CRO) in the
CenterWatch 2017 Global Investigative Site Relationship Survey. The
survey recognizes CROs that have high-quality working relationships
with investigative sites.
The survey, published today in CenterWatch Monthly, polled over
1,300 global investigative sites on aspects of their relationships
with CROs during the past two years. PAREXEL ranked among the top
five highest-rated CROs for the overall quality of its direct
working relationships with investigative sites. In particular,
PAREXEL ranked high in categories such as professional and
efficient administrative staff; professional, knowledgeable, and
well-trained monitors; understanding of local regulatory/ethics
issues; and conduct of clear study initiation visits and
training.
“Across the industry, the relationship between CROs and sites
has become more strategic. To address this need, we have developed
a tailored approach that helps us foster long-term quality
partnerships,” said Paul Evans, Corporate Vice President, Global
Site Strategy, PAREXEL. “PAREXEL’s high ranking is a reflection of
our commitment to our clients and their journeys to bring new
treatments to patients in need.”
PAREXEL’s global Site Alliance Network is a significant
component of the Company’s approach. The network is comprised of
300 sites with dedicated PAREXEL relationship managers. These
individuals also work with key site management organizations (SMOs)
to reach an additional 250 sites. The network includes strategic
collaborations with Academic Research Organizations on two
continents and managed relationships that extend beyond single
studies.
PAREXEL continuously solicits feedback from site staff to
enhance its support. This enables faster patient recruitment,
evaluation, and enrollment in clinical trials. Additionally, the
feedback ensures quality and fosters greater collaboration between
PAREXEL and sites.
“We focus on simplifying trial execution for busy sites and
their staff through our dedicated on-site clinical research
associates, office-based monitors, and other support functions,”
said Karen Chu, Corporate Vice President, Global Clinical
Operations, PAREXEL. “The CenterWatch survey results are a
testament to our focus on delivering effective and timely support
for our sites and our clients.”
CenterWatch’s 2017 Global Investigative Site Relationship Survey
was conducted online between October 2016 and January 2017. The
survey included participation from principal investigators, study
coordinators, and other clinical research professionals from 1,376
sites. More than 80 percent of the sites were from North America
and Europe. The survey, first launched in 1997, uses an instrument
to measure sponsor/site relationship quality based on input from
representatives from sponsor and CRO companies and investigative
sites.
About PAREXEL InternationalPAREXEL International
Corporation is a leading global biopharmaceutical services company,
providing a broad range of expertise-based clinical research,
consulting, medical communications, and technology solutions and
services to the worldwide pharmaceutical, biotechnology, and
medical device industries. Committed to providing solutions that
expedite time-to-market and peak-market penetration, PAREXEL has
developed significant expertise across the development and
commercialization continuum, from drug development and regulatory
consulting to clinical pharmacology, clinical trials management,
and reimbursement. PAREXEL Informatics provides advanced technology
solutions, including medical imaging, to facilitate the clinical
development process. Headquartered near Boston, Massachusetts,
PAREXEL has offices in 85 locations in 51 countries around the
world, and had approximately 19,625 employees in the second
quarter. For more information about PAREXEL International visit
www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its affiliates.
All other trademarks are the property of their respective
owners.
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. Such
factors and others are discussed in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170403005090/en/
Media:Dana RobieTel.: +1 781-434-4772Email:
Dana.Robie@PAREXEL.comorJenny Radloff, PAN CommunicationsTel.: +1
617-502-4300Email: PAREXEL@pancomm.comorInvestors:Ronald
AldridgeTel.: +1 781-434-4753Email: Ron.Aldridge@PAREXEL.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Sep 2023 to Sep 2024